Work

Abstract PS3-08-17: HR+ HER2- Early Breast Cancer (EBC) Patients ≥70 with High Risk 70-gene signature benefit from (Neo)adjuvant chemotherapy (CT): Real World FLEX Study

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps3-08-17

Authors: R. Mahtani, H. Wildiers, S. Lin, S. Ana, A. Schreiber, L. Carcas, N. Dempsey, V. Poillucci, M. Landon, C. Dreezen, H. Ramaswamy, W. Audeh, J. O'Shaughnessy

Institutions: Universitair Ziekenhuis Leuven, University of Colorado Hospital, University of Colorado Anschutz, Agendia (United States), Baylor University Medical Center

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129411231

Cites:

Cited by:

Related to: